View Document Preview and Link Document Date: 2015-03-24 04:43:20 Open Document File Size: 144,16 KB Share Result on Facebook
City Paris / Marseille / / Company QIAGEN / Sham / Matignon Technologies / QIAGEN Marseille / Turenne Capital / HalioDx / HP / Inserm Transfert / HalioDx Vincent Fert / / Country France / United States / / Currency EUR / / / Event M&A / Funding / Business Partnership / FDA Phase / / Facility Paris-Descartes University / Cordeliers Research Center / / IndustryTerm manufacturing teams / mutual insurer / cancer treatment / risk management / manufacturing / / MedicalCondition tumor / cancer / tumors / several solid tumors / solid tumors / advanced melanoma / colon cancer / lung cancer / / MedicalTreatment immunotherapies / / Organization Paris-Descartes University / Cordeliers Research Center / Sham Innovation Santé’s mission / European Union / Scientific Board / / Person Sofipaca Sofipaca / Vincent Fert / Pascale Augé / J. Galon / Jérôme Galon / Inserm Transfert / Marielle Bricman Mob / Judith Aziza Mob / / / Position Director / Research / Vice-President / Medical and Corporate Affairs / CEO / President / President and CEO / Executive / President and Chief Executive Officer / cofounder / Director Research / / Product US / / Technology gene expression / / SocialTag 
Press Release Creation of HalioDx A management buy-out by the QIAGEN Marseille Executive team The ambition to become the reference diagnostic company in immuno-oncology A business model combining immune companion diagnos